Duke logo

Alliance A021502 for Stage III Colon Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug atezolizumab given with the usual chemotherapy is better, the same, or worse than the usual chemotherapy by itself.

What is the Condition Being Studied?

Stage III Colon Cancer

Who Can Participate in the Study?

Adults with Stage III colon cancer who:
- Have a completely resected tumor
- Have no active autoimmune disease
- Are not pregnant or nursing

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomized (put into one of two groups by chance like the flip of a coin) and get either:
-- Group 1: Chemotherapy plus atezolizumab for 6 months, then atezolizumab alone for 6 months
-- Group 2: Chemotherapy for 6 months
- Get a thyroid test before you begin the study drug regimen
- Get a colonoscopy within 6 weeks of completing chemotherapy
- Be asked to complete an optional quality of life questionnaires about your physical and emotional well-being

Study Details

Full Title
Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00087658
NCT:NCT02912559
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698